Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Zeuspaul who wrote (11122)	11/15/1997 12:43:00 AM
From: Courtney Willfore	Read Replies (2) \| Respond to of 32384

Zeuspaul: No. The focus of my posts is towards the posts made by an individual, not the individual per se. The reference to Henry Niman's professional status was simply a reminder that a professional degree can be abused in improper hands. It is the duty, if not the obligation, of a professional scientist to present all sides of an issue. It is NOT an option for a professional to present the positive data while withholding conflicting results. The lack of objective presentation by Dr. Niman in this thread would appear to constitute a conflict of interest. I will not be able to respond further until later this weekend. CW

To: Zeuspaul who wrote (11122)	11/15/1997 12:50:00 AM
From: CYBERKEN	Respond to of 32384

I have a lot of trouble finding the negative angle on Ligand-other than the usual biotech "mights" (Their products might fail in the clinic; the big pharma R & D $$ might dry up-hurting the sector, etc.). In the context of the risks we take more-or-less for granted in investing in biotech, Ligand seems to have excelled in both the scientific and (more important) business areas. That makes it a company I would hold through all the dips, because I believe in the concept that biotech is the best place to invest over the next 5, 10, 20 years. There are a few other companies I feel the same way about, but Ligand's progress over the last 2 years and their prospects make them a favorite. BTW-I bought in long before I ever read any of Henry's posts, but I find his contributions extremely valuable-while recognizing that he might possibly own some of the stock. I don't object to negative posters on the thread, though I find no value in their posts unless they can manage to get down to business and post reasonable, challanging questions about the company or the sector. I have noticed that when the hit-and-run types show up it's generally right before a decent runup in the price. I hope the anecdotal trend holds. One thing I find indicative about hit-and-run posters: They don't seem to waste their time on "dog" threads like Immunogen, Insite Vision, or Genta. Maybe it's some kind of off-handed cybercomplement.